This article is more than 5 years old. Information may no longer be current.

Genentech announces 19% increase in U.S. sales in 2007

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SOUTH SAN FRANCISCO, Calif. — U.S. product sales for Genentech totaled $8.54 billion for the 2007 fiscal year, a 19% increase over sales of $7.17 billion during 2006, the company announced in a press release.

For the fourth quarter 2007, U.S. products sales totaled $2.2 billion, a 7% increase over $2.05 billion for the fourth quarter of 2006. Non-GAAP revenues were $11.72 billion in 2007, a 26% increase from $9.28 billion in 2006. Non-GAAP earnings per share increased 32% to $2.94 per share from $2.23 per share in 2006. Fourth quarter non-GAAP earnings rose 13% to $0.69 per share from $0.61 per share in the fourth quarter of 2006, according to the release.

Full-year GAAP earnings increased 31% to $2.59 per share from $1.97 per share reported for 2006, and fourth quarter GAAP earnings increased 7% to $0.59 per share from $0.55 per share reported for the fourth quarter of 2006.

The company expects non-GAAP earnings between $3.30 and $3.45 per share for the full year 2008, the release said.

Sales of Avastin (bevacizumab) increased 32% in 2007, from $1.75 billion in 2006 to total $2.3 billion. Lucentis (ranibizumab) sales increased 114% during 2007, from $380 million in 2006 to total $815 million, although fourth quarter sales decreased 9% from $217 million in 2006 to $197 million in 2007, the release said.